X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (8622) 8622
Book Review (1978) 1978
Publication (470) 470
Newsletter (286) 286
Newspaper Article (48) 48
Magazine Article (31) 31
Book Chapter (26) 26
Conference Proceeding (26) 26
Dissertation (7) 7
Trade Publication Article (7) 7
Data Set (2) 2
Transcript (2) 2
Web Resource (2) 2
Paper (1) 1
Presentation (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (6786) 6786
humans (6416) 6416
metformin (6206) 6206
female (3907) 3907
diabetes mellitus, type 2 - drug therapy (3561) 3561
male (3338) 3338
hypoglycemic agents - therapeutic use (3297) 3297
type 2 diabetes (2839) 2839
metformin - therapeutic use (2791) 2791
diabetes (2782) 2782
middle aged (2623) 2623
endocrinology & metabolism (2544) 2544
hypoglycemic agents - adverse effects (2341) 2341
aged (1983) 1983
adult (1870) 1870
metformin - adverse effects (1804) 1804
insulin (1724) 1724
glucose (1542) 1542
hypoglycemic agents - administration & dosage (1449) 1449
treatment outcome (1411) 1411
pharmacology & pharmacy (1324) 1324
drug therapy, combination (1283) 1283
drug therapy (1241) 1241
risk factors (1221) 1221
diabetes therapy (1206) 1206
diabetes mellitus, type 2 - blood (1196) 1196
care and treatment (1192) 1192
glycemic control (1192) 1192
diabetes mellitus (1176) 1176
metformin - administration & dosage (1140) 1140
double-blind (1118) 1118
research (1080) 1080
insulin resistance (1060) 1060
mellitus (1041) 1041
hypoglycemic agents (1021) 1021
therapy (967) 967
animals (942) 942
analysis (938) 938
medicine, general & internal (934) 934
blood glucose - metabolism (921) 921
risk (886) 886
clinical trials (825) 825
double-blind method (807) 807
blood glucose - drug effects (775) 775
efficacy (771) 771
health aspects (770) 770
internal medicine (769) 769
abridged index medicus (748) 748
obesity (724) 724
safety (722) 722
diabetes mellitus, type 2 - complications (715) 715
dosage and administration (712) 712
insulin-resistance (708) 708
glycated hemoglobin a - metabolism (685) 685
dextrose (681) 681
hypoglycemic agents - pharmacology (671) 671
mortality (671) 671
metformin - pharmacology (670) 670
hyperglycemia (658) 658
medicine & public health (650) 650
type 2 diabetes mellitus (640) 640
hypoglycemia (619) 619
insulin - therapeutic use (605) 605
complications and side effects (554) 554
body mass index (549) 549
pregnancy (542) 542
sulfonylurea compounds - therapeutic use (533) 533
adolescent (527) 527
thiazolidinediones - therapeutic use (525) 525
management (519) 519
sulfonylurea (501) 501
type-2 diabetes-mellitus (500) 500
patients (491) 491
women (478) 478
studies (470) 470
cancer (469) 469
medical research (468) 468
sitagliptin (466) 466
young adult (466) 466
metabolism (459) 459
aged, 80 and over (455) 455
thiazolidinediones (451) 451
hypoglycemia - chemically induced (448) 448
glycosylated hemoglobin (447) 447
dipeptidyl-peptidase iv inhibitors - therapeutic use (443) 443
drugs (443) 443
body weight (441) 441
glycated hemoglobin a - analysis (441) 441
endocrine system diseases (439) 439
pioglitazone (432) 432
glucagon-like peptide-1 (428) 428
randomized controlled trials as topic (425) 425
rosiglitazone (422) 422
retrospective studies (414) 414
administration, oral (403) 403
nutritional and metabolic diseases (401) 401
pharmacokinetics (395) 395
acidosis, lactic - chemically induced (393) 393
time factors (385) 385
diabetics (384) 384
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (8655) 8655
German (89) 89
Spanish (68) 68
French (60) 60
Dutch (22) 22
Danish (14) 14
Japanese (13) 13
Chinese (12) 12
Russian (12) 12
Italian (11) 11
Swedish (11) 11
Norwegian (8) 8
Polish (8) 8
Czech (7) 7
Korean (7) 7
Hungarian (5) 5
Portuguese (5) 5
Finnish (3) 3
Turkish (3) 3
Bulgarian (1) 1
Croatian (1) 1
Persian (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


ENVIRONMENTAL TOXICOLOGY AND CHEMISTRY, ISSN 0730-7268, 05/2019, Volume 38, Issue 5, pp. 1023 - 1028
Metformin is currently thought to be the highest drug by weight released into the aquatic environment, as a direct result of its widespread use in the... 
Guanylurea | ENVIRONMENTAL SCIENCES | Developmental toxicity | PHARMACOKINETICS | WASTE-WATER | ENVIRONMENT | TOXICOLOGY | Metformin | Nontarget organism toxicity | ANTIDIABETIC DRUG METFORMIN | Pharmaceuticals | Body weight | Adults | Biodegradation | Toxicity | Exposure | Environmental effects | Aquatic environment | Developmental stages | Surface water | Fish | Aquatic organisms | Life cycles
Journal Article
Journal Article
Journal Article
Diabetes Care, ISSN 0149-5992, 2014, Volume 37, Issue 8, pp. 2159 - 2167
OBJECTIVE To compare the efficacy and safety of dulaglutide, a once-weekly GLP-1 receptor agonist, with placebo and exenatide in type 2 diabetic patients. The... 
GLYCEMIC CONTROL | GLUCAGON-LIKE PEPTIDE-1 | EXENDIN-4 | SITAGLIPTIN | ENDOCRINOLOGY & METABOLISM | ANALOG LIRAGLUTIDE | OPEN-LABEL | LY2189265 | TREATED PATIENTS | Recombinant Fusion Proteins - adverse effects | Glucagon-Like Peptides - administration & dosage | Humans | Middle Aged | Male | Immunoglobulin Fc Fragments - administration & dosage | Thiazolidinediones - administration & dosage | Metformin - adverse effects | Peptides - administration & dosage | Hypoglycemic Agents - administration & dosage | Venoms - administration & dosage | Female | Metformin - administration & dosage | Drug Therapy, Combination | Glucagon-Like Peptides - analogs & derivatives | Immunoglobulin Fc Fragments - adverse effects | Recombinant Fusion Proteins - administration & dosage | Drug Administration Schedule | Venoms - adverse effects | Hypoglycemia - drug therapy | Thiazolidinediones - adverse effects | Blood Glucose - drug effects | Glucagon-Like Peptides - adverse effects | Aged | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Peptides - adverse effects | Type 2 diabetes | Care and treatment | Safety and security measures | Dosage and administration | Metformin | Comparative analysis | Exenatide | Clinical trials | Hemoglobin | Diabetes | Product safety | Drug dosages | Placebo effect | Index Medicus
Journal Article
Diabetologia, ISSN 0012-186X, 12/2013, Volume 56, Issue 12, pp. 2582 - 2592
The aim of this work was to evaluate the efficacy and safety of canagliflozin vs placebo and sitagliptin in patients with type 2 diabetes who were being... 
Sodium glucose co-transporter 2 (SGLT2) inhibitor | Medicine & Public Health | Human Physiology | Canagliflozin | Metabolic Diseases | Internal Medicine | Sitagliptin | Metformin | Type 2 diabetes mellitus | GLIPIZIDE | ADD-ON | SULFONYLUREA | DAPAGLIFLOZIN | MELLITUS | INADEQUATE GLYCEMIC CONTROL | DIET | ENDOCRINOLOGY & METABOLISM | DOUBLE-BLIND | 52-WEEK | INHIBITOR | Blood Pressure | Triazoles - administration & dosage | Triazoles - adverse effects | Thiophenes - adverse effects | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Pyrazines - administration & dosage | Glycated Hemoglobin A - drug effects | Body Weight - drug effects | Lipids | Male | Thiophenes - administration & dosage | Metformin - adverse effects | Hypoglycemic Agents - administration & dosage | Aged, 80 and over | Female | Metformin - administration & dosage | Sitagliptin Phosphate | Drug Therapy, Combination | Glucosides - adverse effects | Fasting | Treatment Outcome | Blood Glucose - drug effects | Diabetes Mellitus, Type 2 - blood | Glucosides - administration & dosage | Adolescent | Pyrazines - adverse effects | Aged | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Type 2 diabetes | Complications and side effects | Care and treatment | Body weight | Glucose | Comparative analysis | Dextrose | Index Medicus
Journal Article
JAMA, ISSN 0098-7484, 07/2016, Volume 316, Issue 3, pp. 313 - 324
Journal Article
Diabetes Care, ISSN 0149-5992, 10/2014, Volume 37, Issue 10, pp. 2763 - 2773
OBJECTIVE: Mealtime insulin is commonly added to manage hyperglycemia in type 2 diabetes when basal insulin is insufficient. However, this complex regimen is... 
CONTROLLED-TRIAL | GLYCEMIC CONTROL | ORAL-THERAPY | COMBINATION THERAPY | PARALLEL-GROUP | EXENATIDE | ENDOCRINOLOGY & METABOLISM | OPEN-LABEL | TREATED PATIENTS | TREATMENT SATISFACTION | GETGOAL-L | Glycated Hemoglobin A - analysis | Hypoglycemia - epidemiology | Humans | Middle Aged | Body Weight - drug effects | Male | Hyperglycemia - drug therapy | Metformin - adverse effects | Peptides - administration & dosage | Hypoglycemic Agents - administration & dosage | Venoms - administration & dosage | Female | Metformin - administration & dosage | Hypoglycemia - chemically induced | Meals | Receptors, Glucagon - agonists | Drug Administration Schedule | Venoms - adverse effects | Insulin - administration & dosage | Treatment Outcome | Insulin Lispro - administration & dosage | Blood Glucose - drug effects | Insulin, Long-Acting - adverse effects | Diabetes Mellitus, Type 2 - blood | Insulin, Long-Acting - administration & dosage | Glucagon-Like Peptide-1 Receptor | Insulin Glargine | Insulin Lispro - adverse effects | Quality of Life | Aged | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Insulin - adverse effects | Peptides - adverse effects | Type 2 diabetes | Care and treatment | Dosage and administration | Hypoglycemia | Insulin | Weight gain | Health aspects | Risk factors | Diabetes | Glucose | Medical treatment | Quality of life | Index Medicus
Journal Article
Journal Article